Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan An Interventional, Community Based, Comparative Study
Brief Summary: Fasting during the Ramadan is one of the five pillars of Islam and is a mandatory duty for all healthy adult Muslims. Fasting is considered safe in young healthy subjects but it can induce harmful effects and complications in patients with diabetes. Several studies have demonstrated that patients with type 2 diabetes are prone to hypo and hyper glycemia during fasting. When treating diabetic patients with a treatment guideline the rate of these complications can be reduced. Little data is available on patients with type 2 diabetes treated with insulin. The investigators therefore propose to assess the effect of a protocol containing detemir (levemir) and a premix of insulin aspart (NovoMix70) on glucose control in patients with type 2 diabetes during the Ramadan and to compare this regimen to the standard care patients receive during this period. The investigators assume that patients receiving the intervention will have better glucose control during the Ramadan compared to patients receiving the standard care. As approximately 45 million Muslims suffer from type 2 diabetes and most of them fast during the Ramadan the results of this intervention may be significant and may improve the care of these patients allowing Muslims to respect their religious obligations without compromising their health.


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Other: FAST | Arm Label: Control; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: FAST; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Control
B: Arm Label: Lyxumia; Type: EXPERIMENTAL; Interventions: Drug: Lixisenatide (AVE0010), Drug: metformin, Drug: basal insulin | Arm Label: Sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: metformin, Drug: basal insulin | Intervention Type: DRUG; Name: Lixisenatide (AVE0010); Assigned to Arm(s): Lyxumia | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Sulfonylurea | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Lyxumia, Sulfonylurea | Intervention Type: DRUG; Name: basal insulin; Assigned to Arm(s): Lyxumia, Sulfonylurea
C: Arm Label: 14 days continuous glucose monitoring; Type: OTHER; Interventions: Other: Control period, Dietary Supplement: D-allulose period | Intervention Type: OTHER; Name: Control period; Assigned to Arm(s): 14 days continuous glucose monitoring | Intervention Type: DIETARY_SUPPLEMENT; Name: D-allulose period; Assigned to Arm(s): 14 days continuous glucose monitoring
D: Arm Label: Insulin treatment during Ramadan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin treatment during Ramadan | Arm Label: Standard treatment during Ramadan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of care | Intervention Type: DRUG; Name: Insulin treatment during Ramadan; Assigned to Arm(s): Insulin treatment during Ramadan | Intervention Type: DRUG; Name: Standard of care; Assigned to Arm(s): Standard treatment during Ramadan

Answer: D